Numerical	B:C0679083
simulation	I:C0679083
of	O
emitted	O
particle	I:C0597177
characteristics	O
and	O
airway	O
deposition	O
distribution	O
of	O
Symbicort	O
(	I:C1735945
®)	I:C1735945
Turbuhaler	I:C1735945
(®	I:C1735945
)	I:C1735945
dry	O
powder	I:C0032861
fixed	O
combination	O
aerosol	O
drug	I:C1112870
.	O

Numerical	O
simulation	I:C0679083
of	O
emitted	B:C0597177
particle	I:C0597177
characteristics	O
and	O
airway	O
deposition	O
distribution	O
of	O
Symbicort	O
(	I:C1735945
®)	I:C1735945
Turbuhaler	I:C1735945
(®	I:C1735945
)	I:C1735945
dry	O
powder	I:C0032861
fixed	O
combination	O
aerosol	O
drug	I:C1112870
.	O

Numerical	O
simulation	I:C0679083
of	O
emitted	O
particle	I:C0597177
characteristics	O
and	O
airway	B:C0458827
deposition	O
distribution	O
of	O
Symbicort	O
(	I:C1735945
®)	I:C1735945
Turbuhaler	I:C1735945
(®	I:C1735945
)	I:C1735945
dry	O
powder	I:C0032861
fixed	O
combination	O
aerosol	O
drug	I:C1112870
.	O

Numerical	O
simulation	I:C0679083
of	O
emitted	O
particle	I:C0597177
characteristics	O
and	O
airway	O
deposition	O
distribution	B:C1378698
of	O
Symbicort	O
(	I:C1735945
®)	I:C1735945
Turbuhaler	I:C1735945
(®	I:C1735945
)	I:C1735945
dry	O
powder	I:C0032861
fixed	O
combination	O
aerosol	O
drug	I:C1112870
.	O

Numerical	O
simulation	I:C0679083
of	O
emitted	O
particle	I:C0597177
characteristics	O
and	O
airway	O
deposition	O
distribution	O
of	O
Symbicort	B:C1735945
(	I:C1735945
®)	I:C1735945
Turbuhaler	I:C1735945
(®	I:C1735945
)	I:C1735945
dry	O
powder	I:C0032861
fixed	O
combination	O
aerosol	O
drug	I:C1112870
.	O

Numerical	O
simulation	I:C0679083
of	O
emitted	O
particle	I:C0597177
characteristics	O
and	O
airway	O
deposition	O
distribution	O
of	O
Symbicort	O
(	I:C1735945
®)	I:C1735945
Turbuhaler	I:C1735945
(®	I:C1735945
)	I:C1735945
dry	B:C0032861
powder	I:C0032861
fixed	O
combination	O
aerosol	O
drug	I:C1112870
.	O

Numerical	O
simulation	I:C0679083
of	O
emitted	O
particle	I:C0597177
characteristics	O
and	O
airway	O
deposition	O
distribution	O
of	O
Symbicort	O
(	I:C1735945
®)	I:C1735945
Turbuhaler	I:C1735945
(®	I:C1735945
)	I:C1735945
dry	O
powder	I:C0032861
fixed	O
combination	B:C0013162
aerosol	O
drug	I:C1112870
.	O

Numerical	O
simulation	I:C0679083
of	O
emitted	O
particle	I:C0597177
characteristics	O
and	O
airway	O
deposition	O
distribution	O
of	O
Symbicort	O
(	I:C1735945
®)	I:C1735945
Turbuhaler	I:C1735945
(®	I:C1735945
)	I:C1735945
dry	O
powder	I:C0032861
fixed	O
combination	O
aerosol	B:C1112870
drug	I:C1112870
.	O

One	O
of	O
the	O
most	O
widespread	O
dry	B:C0032861
powder	I:C0032861
fixed	O
combinations	O
used	O
in	O
asthma	O
and	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
(	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
)	O
management	O
is	O
Symbicort	O
(	I:C1735945
®	I:C1735945
)	I:C1735945
Turbuhaler	I:C1735945
(	I:C1735945
®	I:C1735945
)	I:C1735945
.	O

One	O
of	O
the	O
most	O
widespread	O
dry	O
powder	I:C0032861
fixed	O
combinations	B:C0013162
used	O
in	O
asthma	O
and	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
(	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
)	O
management	O
is	O
Symbicort	O
(	I:C1735945
®	I:C1735945
)	I:C1735945
Turbuhaler	I:C1735945
(	I:C1735945
®	I:C1735945
)	I:C1735945
.	O

One	O
of	O
the	O
most	O
widespread	O
dry	O
powder	I:C0032861
fixed	O
combinations	O
used	O
in	O
asthma	B:C0004096
and	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
(	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
)	O
management	O
is	O
Symbicort	O
(	I:C1735945
®	I:C1735945
)	I:C1735945
Turbuhaler	I:C1735945
(	I:C1735945
®	I:C1735945
)	I:C1735945
.	O

One	O
of	O
the	O
most	O
widespread	O
dry	O
powder	I:C0032861
fixed	O
combinations	O
used	O
in	O
asthma	O
and	O
chronic	B:C0024117
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
(	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
)	O
management	O
is	O
Symbicort	O
(	I:C1735945
®	I:C1735945
)	I:C1735945
Turbuhaler	I:C1735945
(	I:C1735945
®	I:C1735945
)	I:C1735945
.	O

One	O
of	O
the	O
most	O
widespread	O
dry	O
powder	I:C0032861
fixed	O
combinations	O
used	O
in	O
asthma	O
and	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
(	O
chronic	B:C0024117
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
)	O
management	O
is	O
Symbicort	O
(	I:C1735945
®	I:C1735945
)	I:C1735945
Turbuhaler	I:C1735945
(	I:C1735945
®	I:C1735945
)	I:C1735945
.	O

One	O
of	O
the	O
most	O
widespread	O
dry	O
powder	I:C0032861
fixed	O
combinations	O
used	O
in	O
asthma	O
and	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
(	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
)	O
management	B:C0376636
is	O
Symbicort	O
(	I:C1735945
®	I:C1735945
)	I:C1735945
Turbuhaler	I:C1735945
(	I:C1735945
®	I:C1735945
)	I:C1735945
.	O

One	O
of	O
the	O
most	O
widespread	O
dry	O
powder	I:C0032861
fixed	O
combinations	O
used	O
in	O
asthma	O
and	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
(	O
chronic	O
obstructive	I:C0024117
pulmonary	I:C0024117
disease	I:C0024117
)	O
management	O
is	O
Symbicort	B:C1735945
(	I:C1735945
®	I:C1735945
)	I:C1735945
Turbuhaler	I:C1735945
(	I:C1735945
®	I:C1735945
)	I:C1735945
.	O

The	O
aim	O
of	O
this	O
study	B:C2603343
was	O
to	O
simulate	O
the	O
deposition	O
distribution	O
of	O
both	O
components	O
of	O
this	O
drug	O
within	O
the	O
airways	O
based	O
on	O
realistic	O
airflow	O
measurements	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
simulate	B:C0679083
the	O
deposition	O
distribution	O
of	O
both	O
components	O
of	O
this	O
drug	O
within	O
the	O
airways	O
based	O
on	O
realistic	O
airflow	O
measurements	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
simulate	O
the	O
deposition	O
distribution	B:C1378698
of	O
both	O
components	O
of	O
this	O
drug	O
within	O
the	O
airways	O
based	O
on	O
realistic	O
airflow	O
measurements	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
simulate	O
the	O
deposition	O
distribution	O
of	O
both	O
components	O
of	O
this	O
drug	B:C1254351
within	O
the	O
airways	O
based	O
on	O
realistic	O
airflow	O
measurements	O
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
simulate	O
the	O
deposition	O
distribution	O
of	O
both	O
components	O
of	O
this	O
drug	O
within	O
the	O
airways	B:C0458827
based	O
on	O
realistic	O
airflow	O
measurements	O
.	O

Breathing	B:C0004048
parameters	O
of	O
25	O
healthy	O
adults	I:C0686750
(	O
11	O
females	O
and	O
14	O
males	O
)	O
were	O
acquired	O
while	O
inhaling	O
through	O
Turbuhaler	O
(	I:C1553479
®	I:C1553479
)	I:C1553479
.	O

Breathing	O
parameters	O
of	O
25	O
healthy	B:C0686750
adults	I:C0686750
(	O
11	O
females	O
and	O
14	O
males	O
)	O
were	O
acquired	O
while	O
inhaling	O
through	O
Turbuhaler	O
(	I:C1553479
®	I:C1553479
)	I:C1553479
.	O

Breathing	O
parameters	O
of	O
25	O
healthy	O
adults	I:C0686750
(	O
11	O
females	O
and	O
14	O
males	O
)	O
were	O
acquired	O
while	O
inhaling	B:C0004048
through	O
Turbuhaler	O
(	I:C1553479
®	I:C1553479
)	I:C1553479
.	O

Breathing	O
parameters	O
of	O
25	O
healthy	O
adults	I:C0686750
(	O
11	O
females	O
and	O
14	O
males	O
)	O
were	O
acquired	O
while	O
inhaling	O
through	O
Turbuhaler	B:C1553479
(	I:C1553479
®	I:C1553479
)	I:C1553479
.	O

Individual	B:C0027361
specific	O
emitted	O
doses	O
and	O
particle	O
size	O
distributions	O
of	O
Symbicort	O
(	I:C1735945
®)	I:C1735945
Turbuhaler	I:C1735945
(®	I:C1735945
)	I:C1735945
were	O
determined	O
.	O

Individual	O
specific	O
emitted	O
doses	O
and	O
particle	O
size	O
distributions	B:C1378698
of	O
Symbicort	O
(	I:C1735945
®)	I:C1735945
Turbuhaler	I:C1735945
(®	I:C1735945
)	I:C1735945
were	O
determined	O
.	O

Individual	O
specific	O
emitted	O
doses	O
and	O
particle	O
size	O
distributions	O
of	O
Symbicort	B:C1735945
(	I:C1735945
®)	I:C1735945
Turbuhaler	I:C1735945
(®	I:C1735945
)	I:C1735945
were	O
determined	O
.	O

A	O
self	O
-	O
developed	O
particle	B:C0597177
deposition	O
model	O
was	O
adapted	O
and	O
validated	O
to	O
simulate	O
the	O
deposition	O
of	O
budesonide	O
(	O
inhaled	O
corticosteroid	I:C1629043
;	O
ICS	O
)	O
and	O
formoterol	O
(	O
long	O
acting	I:C2987634
β	I:C2987634
2	I:C2987634
agonist	I:C2987634
;	O
LABA	O
)	O
in	O
the	O
upper	O
airways	I:C0225377
and	O
lungs	O
of	O
the	O
healthy	O
volunteers	I:C1708335
.	O

A	O
self	O
-	O
developed	O
particle	O
deposition	O
model	B:C3161035
was	O
adapted	O
and	O
validated	O
to	O
simulate	O
the	O
deposition	O
of	O
budesonide	O
(	O
inhaled	O
corticosteroid	I:C1629043
;	O
ICS	O
)	O
and	O
formoterol	O
(	O
long	O
acting	I:C2987634
β	I:C2987634
2	I:C2987634
agonist	I:C2987634
;	O
LABA	O
)	O
in	O
the	O
upper	O
airways	I:C0225377
and	O
lungs	O
of	O
the	O
healthy	O
volunteers	I:C1708335
.	O

A	O
self	O
-	O
developed	O
particle	O
deposition	O
model	O
was	O
adapted	O
and	O
validated	O
to	O
simulate	B:C0679083
the	O
deposition	O
of	O
budesonide	O
(	O
inhaled	O
corticosteroid	I:C1629043
;	O
ICS	O
)	O
and	O
formoterol	O
(	O
long	O
acting	I:C2987634
β	I:C2987634
2	I:C2987634
agonist	I:C2987634
;	O
LABA	O
)	O
in	O
the	O
upper	O
airways	I:C0225377
and	O
lungs	O
of	O
the	O
healthy	O
volunteers	I:C1708335
.	O

A	O
self	O
-	O
developed	O
particle	O
deposition	O
model	O
was	O
adapted	O
and	O
validated	O
to	O
simulate	O
the	O
deposition	O
of	O
budesonide	B:C0054201
(	O
inhaled	O
corticosteroid	I:C1629043
;	O
ICS	O
)	O
and	O
formoterol	O
(	O
long	O
acting	I:C2987634
β	I:C2987634
2	I:C2987634
agonist	I:C2987634
;	O
LABA	O
)	O
in	O
the	O
upper	O
airways	I:C0225377
and	O
lungs	O
of	O
the	O
healthy	O
volunteers	I:C1708335
.	O

A	O
self	O
-	O
developed	O
particle	O
deposition	O
model	O
was	O
adapted	O
and	O
validated	O
to	O
simulate	O
the	O
deposition	O
of	O
budesonide	O
(	O
inhaled	B:C1629043
corticosteroid	I:C1629043
;	O
ICS	O
)	O
and	O
formoterol	O
(	O
long	O
acting	I:C2987634
β	I:C2987634
2	I:C2987634
agonist	I:C2987634
;	O
LABA	O
)	O
in	O
the	O
upper	O
airways	I:C0225377
and	O
lungs	O
of	O
the	O
healthy	O
volunteers	I:C1708335
.	O

A	O
self	O
-	O
developed	O
particle	O
deposition	O
model	O
was	O
adapted	O
and	O
validated	O
to	O
simulate	O
the	O
deposition	O
of	O
budesonide	O
(	O
inhaled	O
corticosteroid	I:C1629043
;	O
ICS	B:C1629043
)	O
and	O
formoterol	O
(	O
long	O
acting	I:C2987634
β	I:C2987634
2	I:C2987634
agonist	I:C2987634
;	O
LABA	O
)	O
in	O
the	O
upper	O
airways	I:C0225377
and	O
lungs	O
of	O
the	O
healthy	O
volunteers	I:C1708335
.	O

A	O
self	O
-	O
developed	O
particle	O
deposition	O
model	O
was	O
adapted	O
and	O
validated	O
to	O
simulate	O
the	O
deposition	O
of	O
budesonide	O
(	O
inhaled	O
corticosteroid	I:C1629043
;	O
ICS	O
)	O
and	O
formoterol	B:C0060657
(	O
long	O
acting	I:C2987634
β	I:C2987634
2	I:C2987634
agonist	I:C2987634
;	O
LABA	O
)	O
in	O
the	O
upper	O
airways	I:C0225377
and	O
lungs	O
of	O
the	O
healthy	O
volunteers	I:C1708335
.	O

A	O
self	O
-	O
developed	O
particle	O
deposition	O
model	O
was	O
adapted	O
and	O
validated	O
to	O
simulate	O
the	O
deposition	O
of	O
budesonide	O
(	O
inhaled	O
corticosteroid	I:C1629043
;	O
ICS	O
)	O
and	O
formoterol	O
(	O
long	B:C2987634
acting	I:C2987634
β	I:C2987634
2	I:C2987634
agonist	I:C2987634
;	O
LABA	O
)	O
in	O
the	O
upper	O
airways	I:C0225377
and	O
lungs	O
of	O
the	O
healthy	O
volunteers	I:C1708335
.	O

A	O
self	O
-	O
developed	O
particle	O
deposition	O
model	O
was	O
adapted	O
and	O
validated	O
to	O
simulate	O
the	O
deposition	O
of	O
budesonide	O
(	O
inhaled	O
corticosteroid	I:C1629043
;	O
ICS	O
)	O
and	O
formoterol	O
(	O
long	O
acting	I:C2987634
β	I:C2987634
2	I:C2987634
agonist	I:C2987634
;	O
LABA	B:C2987634
)	O
in	O
the	O
upper	O
airways	I:C0225377
and	O
lungs	O
of	O
the	O
healthy	O
volunteers	I:C1708335
.	O

A	O
self	O
-	O
developed	O
particle	O
deposition	O
model	O
was	O
adapted	O
and	O
validated	O
to	O
simulate	O
the	O
deposition	O
of	O
budesonide	O
(	O
inhaled	O
corticosteroid	I:C1629043
;	O
ICS	O
)	O
and	O
formoterol	O
(	O
long	O
acting	I:C2987634
β	I:C2987634
2	I:C2987634
agonist	I:C2987634
;	O
LABA	O
)	O
in	O
the	O
upper	B:C0225377
airways	I:C0225377
and	O
lungs	O
of	O
the	O
healthy	O
volunteers	I:C1708335
.	O

A	O
self	O
-	O
developed	O
particle	O
deposition	O
model	O
was	O
adapted	O
and	O
validated	O
to	O
simulate	O
the	O
deposition	O
of	O
budesonide	O
(	O
inhaled	O
corticosteroid	I:C1629043
;	O
ICS	O
)	O
and	O
formoterol	O
(	O
long	O
acting	I:C2987634
β	I:C2987634
2	I:C2987634
agonist	I:C2987634
;	O
LABA	O
)	O
in	O
the	O
upper	O
airways	I:C0225377
and	O
lungs	B:C0024109
of	O
the	O
healthy	O
volunteers	I:C1708335
.	O

A	O
self	O
-	O
developed	O
particle	O
deposition	O
model	O
was	O
adapted	O
and	O
validated	O
to	O
simulate	O
the	O
deposition	O
of	O
budesonide	O
(	O
inhaled	O
corticosteroid	I:C1629043
;	O
ICS	O
)	O
and	O
formoterol	O
(	O
long	O
acting	I:C2987634
β	I:C2987634
2	I:C2987634
agonist	I:C2987634
;	O
LABA	O
)	O
in	O
the	O
upper	O
airways	I:C0225377
and	O
lungs	O
of	O
the	O
healthy	B:C1708335
volunteers	I:C1708335
.	O

Based	O
on	O
current	O
simulations	B:C0679083
the	O
emitted	O
doses	O
varied	O
between	O
50.4	O
%	O
and	O
92.5	O
%	O
of	O
the	O
metered	O
dose	O
for	O
the	O
ICS	O
,	O
and	O
between	O
38	O
%	O
and	O
96.1	O
%	O
in	O
case	O
of	O
LABA	O
component	O
depending	O
on	O
the	O
individual	O
inhalation	O
flow	I:C0231832
rate	I:C0231832
.	O

Based	O
on	O
current	O
simulations	O
the	O
emitted	O
doses	O
varied	O
between	O
50.4	O
%	O
and	O
92.5	O
%	O
of	O
the	O
metered	O
dose	O
for	O
the	O
ICS	B:C1629043
,	O
and	O
between	O
38	O
%	O
and	O
96.1	O
%	O
in	O
case	O
of	O
LABA	O
component	O
depending	O
on	O
the	O
individual	O
inhalation	O
flow	I:C0231832
rate	I:C0231832
.	O

Based	O
on	O
current	O
simulations	O
the	O
emitted	O
doses	O
varied	O
between	O
50.4	O
%	O
and	O
92.5	O
%	O
of	O
the	O
metered	O
dose	O
for	O
the	O
ICS	O
,	O
and	O
between	O
38	O
%	O
and	O
96.1	O
%	O
in	O
case	O
of	O
LABA	B:C2987634
component	O
depending	O
on	O
the	O
individual	O
inhalation	O
flow	I:C0231832
rate	I:C0231832
.	O

Based	O
on	O
current	O
simulations	O
the	O
emitted	O
doses	O
varied	O
between	O
50.4	O
%	O
and	O
92.5	O
%	O
of	O
the	O
metered	O
dose	O
for	O
the	O
ICS	O
,	O
and	O
between	O
38	O
%	O
and	O
96.1	O
%	O
in	O
case	O
of	O
LABA	O
component	O
depending	O
on	O
the	O
individual	B:C0027361
inhalation	O
flow	I:C0231832
rate	I:C0231832
.	O

Based	O
on	O
current	O
simulations	O
the	O
emitted	O
doses	O
varied	O
between	O
50.4	O
%	O
and	O
92.5	O
%	O
of	O
the	O
metered	O
dose	O
for	O
the	O
ICS	O
,	O
and	O
between	O
38	O
%	O
and	O
96.1	O
%	O
in	O
case	O
of	O
LABA	O
component	O
depending	O
on	O
the	O
individual	O
inhalation	B:C0231832
flow	I:C0231832
rate	I:C0231832
.	O

This	O
variability	O
induced	O
a	O
notable	O
inter-	O
individual	B:C0027361
spread	O
of	O
the	O
deposited	O
lung	O
doses	O
(	O
mean	O
:	O
33.6	O
%	O
,	O
range	O
:	O
20.4	O
%	O
-	O
48.8	O
%	O
for	O
budesonide	O
and	O
mean	O
:	O
29.8	O
%	O
,	O
range	O
:	O
16.4	O
%	O
-	O
42.9	O
%	O
for	O
formoterol	O
)	O
.	O

This	O
variability	O
induced	O
a	O
notable	O
inter-	O
individual	O
spread	O
of	O
the	O
deposited	O
lung	B:C0024109
doses	O
(	O
mean	O
:	O
33.6	O
%	O
,	O
range	O
:	O
20.4	O
%	O
-	O
48.8	O
%	O
for	O
budesonide	O
and	O
mean	O
:	O
29.8	O
%	O
,	O
range	O
:	O
16.4	O
%	O
-	O
42.9	O
%	O
for	O
formoterol	O
)	O
.	O

This	O
variability	O
induced	O
a	O
notable	O
inter-	O
individual	O
spread	O
of	O
the	O
deposited	O
lung	O
doses	O
(	O
mean	O
:	O
33.6	O
%	O
,	O
range	O
:	O
20.4	O
%	O
-	O
48.8	O
%	O
for	O
budesonide	B:C0054201
and	O
mean	O
:	O
29.8	O
%	O
,	O
range	O
:	O
16.4	O
%	O
-	O
42.9	O
%	O
for	O
formoterol	O
)	O
.	O

This	O
variability	O
induced	O
a	O
notable	O
inter-	O
individual	O
spread	O
of	O
the	O
deposited	O
lung	O
doses	O
(	O
mean	O
:	O
33.6	O
%	O
,	O
range	O
:	O
20.4	O
%	O
-	O
48.8	O
%	O
for	O
budesonide	O
and	O
mean	O
:	O
29.8	O
%	O
,	O
range	O
:	O
16.4	O
%	O
-	O
42.9	O
%	O
for	O
formoterol	B:C0060657
)	O
.	O

Average	O
lung	B:C0024109
dose	O
of	O
budesonide	O
was	O
29.2	O
%	O
of	O
the	O
metered	O
dose	O
for	O
females	O
and	O
37	O
%	O
for	O
males	O
,	O
while	O
formoterol	O
deposited	O
with	O
26.4	O
%	O
efficiency	O
for	O
females	O
and	O
32.5	O
%	O
for	O
males	O
.	O

Average	O
lung	O
dose	O
of	O
budesonide	B:C0054201
was	O
29.2	O
%	O
of	O
the	O
metered	O
dose	O
for	O
females	O
and	O
37	O
%	O
for	O
males	O
,	O
while	O
formoterol	O
deposited	O
with	O
26.4	O
%	O
efficiency	O
for	O
females	O
and	O
32.5	O
%	O
for	O
males	O
.	O

Average	O
lung	O
dose	O
of	O
budesonide	O
was	O
29.2	O
%	O
of	O
the	O
metered	O
dose	O
for	O
females	O
and	O
37	O
%	O
for	O
males	O
,	O
while	O
formoterol	B:C0060657
deposited	O
with	O
26.4	O
%	O
efficiency	O
for	O
females	O
and	O
32.5	O
%	O
for	O
males	O
.	O

Present	O
results	O
also	O
highlighted	O
the	O
importance	O
of	O
breath	B:C0235744
-	I:C0235744
holding	I:C0235744
after	O
inhalation	O
of	O
the	O
drug	O
.	O

Present	O
results	O
also	O
highlighted	O
the	O
importance	O
of	O
breath	O
-	I:C0235744
holding	I:C0235744
after	O
inhalation	B:C0004048
of	O
the	O
drug	O
.	O

Present	O
results	O
also	O
highlighted	O
the	O
importance	O
of	O
breath	O
-	I:C0235744
holding	I:C0235744
after	O
inhalation	O
of	O
the	O
drug	B:C1254351
.	O

About	O
a	O
half	O
of	O
the	O
total	O
lung	B:C0024109
deposition	O
occurred	O
during	O
breath	O
-	I:C0235744
hold	I:C0235744
at	O
9.6s	O
average	O
breath	O
-	I:C0235744
hold	I:C0235744
time	O
.	O

About	O
a	O
half	O
of	O
the	O
total	O
lung	O
deposition	O
occurred	O
during	O
breath	B:C0235744
-	I:C0235744
hold	I:C0235744
at	O
9.6s	O
average	O
breath	O
-	I:C0235744
hold	I:C0235744
time	O
.	O

About	O
a	O
half	O
of	O
the	O
total	O
lung	O
deposition	O
occurred	O
during	O
breath	O
-	I:C0235744
hold	I:C0235744
at	O
9.6s	O
average	O
breath	B:C0235744
-	I:C0235744
hold	I:C0235744
time	O
.	O

Calculated	O
depositions	O
confirmed	O
appropriate	O
lung	B:C0024109
deposition	O
of	O
Symbicort	O
(®)	I:C1735945
Turbuhaler	I:C1735945
(®	I:C1735945
)	I:C1735945
for	O
both	O
genders	O
,	O
however	O
more	O
effort	O
for	O
optimal	O
inhalation	I:C1998547
technique	I:C1998547
is	O
advised	O
for	O
persons	O
with	O
low	O
vital	I:C0476408
capacity	I:C0476408
.	O

Calculated	O
depositions	O
confirmed	O
appropriate	O
lung	O
deposition	O
of	O
Symbicort	B:C1735945
(®)	I:C1735945
Turbuhaler	I:C1735945
(®	I:C1735945
)	I:C1735945
for	O
both	O
genders	O
,	O
however	O
more	O
effort	O
for	O
optimal	O
inhalation	I:C1998547
technique	I:C1998547
is	O
advised	O
for	O
persons	O
with	O
low	O
vital	I:C0476408
capacity	I:C0476408
.	O

Calculated	O
depositions	O
confirmed	O
appropriate	O
lung	O
deposition	O
of	O
Symbicort	O
(®)	I:C1735945
Turbuhaler	I:C1735945
(®	I:C1735945
)	I:C1735945
for	O
both	O
genders	O
,	O
however	O
more	O
effort	O
for	O
optimal	B:C1998547
inhalation	I:C1998547
technique	I:C1998547
is	O
advised	O
for	O
persons	O
with	O
low	O
vital	I:C0476408
capacity	I:C0476408
.	O

Calculated	O
depositions	O
confirmed	O
appropriate	O
lung	O
deposition	O
of	O
Symbicort	O
(®)	I:C1735945
Turbuhaler	I:C1735945
(®	I:C1735945
)	I:C1735945
for	O
both	O
genders	O
,	O
however	O
more	O
effort	O
for	O
optimal	O
inhalation	I:C1998547
technique	I:C1998547
is	O
advised	O
for	O
persons	B:C0027361
with	O
low	O
vital	I:C0476408
capacity	I:C0476408
.	O

Calculated	O
depositions	O
confirmed	O
appropriate	O
lung	O
deposition	O
of	O
Symbicort	O
(®)	I:C1735945
Turbuhaler	I:C1735945
(®	I:C1735945
)	I:C1735945
for	O
both	O
genders	O
,	O
however	O
more	O
effort	O
for	O
optimal	O
inhalation	I:C1998547
technique	I:C1998547
is	O
advised	O
for	O
persons	O
with	O
low	B:C0476408
vital	I:C0476408
capacity	I:C0476408
.	O

This	O
study	B:C2603343
demonstrated	O
the	O
possibility	O
of	O
personalized	O
prediction	O
of	O
airway	O
deposition	O
of	O
aerosol	O
drugs	I:C1112870
by	O
numerical	O
simulations	I:C0679083
.	O

This	O
study	O
demonstrated	O
the	O
possibility	O
of	O
personalized	O
prediction	O
of	O
airway	B:C0458827
deposition	O
of	O
aerosol	O
drugs	I:C1112870
by	O
numerical	O
simulations	I:C0679083
.	O

This	O
study	O
demonstrated	O
the	O
possibility	O
of	O
personalized	O
prediction	O
of	O
airway	O
deposition	O
of	O
aerosol	B:C1112870
drugs	I:C1112870
by	O
numerical	O
simulations	I:C0679083
.	O

This	O
study	O
demonstrated	O
the	O
possibility	O
of	O
personalized	O
prediction	O
of	O
airway	O
deposition	O
of	O
aerosol	O
drugs	I:C1112870
by	O
numerical	B:C0679083
simulations	I:C0679083
.	O

The	O
methodology	O
developed	O
in	O
this	O
study	B:C2603343
will	O
be	O
applicable	O
also	O
to	O
other	O
marketed	O
drugs	O
in	O
the	O
future	O
.	O

The	O
methodology	O
developed	O
in	O
this	O
study	O
will	O
be	O
applicable	O
also	O
to	O
other	O
marketed	O
drugs	B:C1254351
in	O
the	O
future	O
.	O

